Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Shortage Plan Would Grade Firms To Encourage High-Quality Production

Executive Summary

US FDA task force recommends a rating system that purchasers could rely on to reward manufacturers with robust management systems.

You may also be interested in...



Supply Chain Resilience Measures Included In Senate Coronavirus Bill

Whether major drug shortages result from the COVID-19 pandemic or not, manufacturers would face greater reporting requirements, especially for APIs.

Trump Counts On China To Deliver In The Day Of The Coronavirus

President dismisses fears of drug shortages as White House prepares to deliver US from dependence on China’s pharmaceutical manufacturing complex.

Drug Shortage Legislation Gains Support As Coronavirus Threatens US Supplies

Coronavirus hysteria sweeps up languishing drug shortage legislation; prospects for new reporting and risk management planning requirements improve.

Related Content

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel